Chardan Capital Downgrades Oncorus to Neutral

Chardan Capital analyst Matthew Barcus downgrades Oncorus (NASDAQ:ONCR) from Buy to Neutral.

byBenzinga Newsdesk

December 1, 2022

1 minute read

Chardan Capital analyst Matthew Barcus downgrades Oncorus (NASDAQ:ONCR) from Buy to Neutral.

Prince Harry, Meghan Visit Oprah: Will They Surprise Queen Elizabeth With Another Tell-All Interview?

By Shivdeep Dhaliwal

Today, 2:59 AM

Prince Harry and Meghan Markle were spotted visiting Oprah Winfrey over the weekend, spurring rumors of another tell-all interview, according to a report.

NFLX

Pfizer, BioNTech Offers Update On Rolling Submission For Emergency Use Authorization Of COVID-19 Vaccine In Children 6 Months To 4 Years

By Benzinga Newsdesk

Today, 2:59 AM

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) today announced plans to extend their rolling submission to the U.S. Food and Drug Administration (FDA) seeking to amend the Emergency Use Authorization of the

BNTX

SVB Leerink Maintains Market Perform on Solid Biosciences, Raises Price Target to $6

By Benzinga Newsdesk

Today, 2:59 AM

SVB Leerink analyst Joseph Schwartz maintains Solid Biosciences (NASDAQ:SLDB) with a Market Perform and raises the price target from $1 to $6.

SLDB

VNET Shares Pop As Fitch Sees Robust Data Center Demand From Alibaba

By Anusuya Lahiri

Today, 2:59 AM

Fitch Ratings has affirmed China-based carrier-neutral data center operator VNET Group Inc’s (NASDAQ:VNET) Long-Term Foreign- and Local-Currency Issuer Default Ratings (IDRs) at…

BABA

Chardan Capital Downgrades Oncorus to Neutral

Related Posts

Prince Harry, Meghan Visit Oprah: Will They Surprise Queen Elizabeth With Another Tell-All Interview?

Pfizer, BioNTech Offers Update On Rolling Submission For Emergency Use Authorization Of COVID-19 Vaccine In Children 6 Months To 4 Years

SVB Leerink Maintains Market Perform on Solid Biosciences, Raises Price Target to $6

VNET Shares Pop As Fitch Sees Robust Data Center Demand From Alibaba